Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Biotech startups are built on venture capital. Track funding rounds ...
Nov 21, 2024 · With the funding of two startups this week, OrbiMed has passed Alexandria Venture Investments to become the third most active biotech investor since 2022, according to BioPharma Dive data.
The biopharma industry outlook on 2024: Guarded optimism for a …
Jan 16, 2024 · Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024.. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a more strident Federal Trade Commission, further weighed on the sector.. There are now some signs of a turnaround, from a rebounding ...
Summit lung cancer drug shows ‘striking’ benefit over Keytruda
Sep 8, 2024 · Discovered by the China-based biotech Akeso, ivonescimab works differently than Keytruda, which blocks the immune-regulating protein PD-1. Rather, it simultaneously stifles PD-1 and another target implicated in tumor growth, called VEGF.
Investors put $400M into biotech licensing obesity drugs from China
May 16, 2024 · Four life science investors are pouring $400 million into a new biotechnology startup that’s licensed a portfolio of weight loss medicines from Chinese drugmaker Jiangsu Hengrui Pharmaceuticals, according to a disclosure posted on the Shanghai Stock Exchange Thursday.. The newly created company, currently referred to as “Hercules CM NewCo,” is backed by Bain Capital Life Sciences, RTW ...
Pfizer, under pressure to change, names oncology head as new …
Nov 20, 2024 · “Dr. Boshoff is the ideal leader to propel Pfizer’s R&D engine forward and transform it into a world-leading organization with a more focused strategy,” Pfizer CEO Albert Bourla said in the company’s statement.He credited Boshoff with running one of the company’s most productive divisions and said he has a “compelling vision” for …
The golden era of GLP-1 drugs: Where we are and what comes next
Sep 23, 2024 · A guidance from the U.S. FDA (draft updated in March 2020) requires data on cardiovascular events in new T2D drug development programs.As a result, dedicated cardiovascular safety trials were implemented. Many demonstrated beneficial effects of GLP-1 RAs on the heart and kidneys in patients with T2D (with and without preexisting conditions), with those effects thought to be largely independent ...
Drug patents protect pharma profits. Track when they’ll expire.
May 8, 2024 · Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The legal monopoly that patents provide keeps generic copies at bay for many years, even decades, and allows pharmaceutical companies to set higher prices than they otherwise could.
A decade of cancer immunotherapy: Keytruda, Opdivo and the …
Sep 4, 2024 · Developed by Bristol Myers Squibb, Opdivo was the second so-called PD1 inhibitor to be approved in the U.S. The first, Merck & Co.’s Keytruda, won Food and Drug Administration clearance 10 years ago today. Keytruda’s initial U.S. approval, which preceded Opdivo’s by a few months, was niche, reserved for people with inoperable melanoma or whose disease had spread and couldn’t be ...
Zepbound, Mounjaro back in supply as Lilly resolves shortage
Aug 5, 2024 · Dive Insight: Lilly has been pouring money into expanding its manufacturing capacity for tirzepatide by opening production at more of its existing facilities, buying factories and building new ones.Still, it hasn’t been able to make tirzepatide fast enough, as demand for the drug and Novo Nordisk’s rival medicines Ozempic and Wegovy soared.